Pfizer co.jp Home | Corporate Profile | Business Outline | Phermaceuticals Business | Research & Development PGRD* Nagoya Laboratories Global teamwork and cutting-edge technology lead to safe, innovative medicines. Having discovered more than 25 Candidates (potential new medicines) over the past 15 years, PGRD* Nagoya Laboratories is an important part of Pfizer's global R&D network. The Nagoya site has been engaged in research to develop new analgesic medicines since 1992, as well as drugs for gastro-intestinal（G.I.） disorders since 2000 and for liver diseases that were newly added in late 2004. Pharmaceutical R&D begins by studying disease mechanisms on a genetic/molecular level. It advances with the identification of functional molecules, which are screened in the search for chemical compounds capable of achieving reliable therapeutic results. Once a promising chemical compound is detected, its efficacy and safety are thoroughly assessed. The few compounds that pass these rigorous tests then enter another selection process involving further cooperation among Nagoya laboratories and those in the U.S. and Europe. In the search for new leading compounds, Nagoya laboratories has been effectively employing high-speed robotics in order to screen the millions of compounds necessary for success. To bring Candidates discovered overseas into Japan, Nagoya laboratories also assists in preparing government applications by collecting data in collaboration with the Clinical Development Division. *Pfizer Global Research and Development J-clin, PGRD Tokyo Laboratories J-clin spirit of global collaboration leads international clinical development. Based in Tokyo, J-clin functions as Pfizer's clinical development organization, dedicated to the promotion of information exchanges and collaborative efforts with other Pfizer R&D facilities. Vast amounts of clinical data are available from Pfizer U.S. and Europe, and J-clin works to make effective use of it. Responsibilities in connection with the ICH*conference are also a part of the role J-clin fulfills. J-clin works to achieve Pfizer's collective goal of simultaneous new product development and worldwide drug approval. In addition, J-clin facilitates Pfizer's global clinical development process by promoting improved cooperation with marketing personnel. This allows maximized market value of new pharmaceutical products and accelerates the development of innovative medicines. *The International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH). Initiated in 1991, the ICH works to expedite regulatory approvals by sharing clinical test data globally and thereby eliminate the need for duplication of studies for each jurisdiction.